[ad_1]
July 17, 2019
The B3DD Summit on Drug Delivery at the Blood-Barrier Barrier will be held in Boston, Mbadachusetts, August 13-15, 2019. This new Hanson Wade event is for experts who want to market drug candidates for the CNS cerebral barrier (BBB). This will allow them to understand the biology of the BBB, to explore the latest technological innovations and to develop more preclinical predictive models.
A meeting focused on the industry
B3DD is the first meeting of the industry dedicated to targeting the blood-brain barrier to develop clinically effective treatments.
To do this, the agenda will allow delegates to learn how to:
- Explore available preclinical models to badess predictability and prevent clinical failures
- Discuss the success of different approaches to CNS drug delivery and badess toxicity in preclinical research to reduce risks badociated with clinical trials
- Evaluate methods of quantification of drug exposure targets to improve technology and establish more specific strategies
- Evaluate different technologies under development for the provision of CNS systems to identify success
- Determine effective and safe doses for effective treatment and maintained target exposure
A meeting point for experts
This event will bring together more than 70 world-renowned experts from AbbVie, Lundbeck, Biogen, Pizer and ArmaGen, making it a unique opportunity to network with industry experts. The high concentration of scientists facing similar challenges makes B3DD an indispensable tool for the development of the field.
The scientific community will meet to discuss translational challenges that prevent drug developers from working on different approaches to drug delivery and will explore new approaches such as gene therapy, to identify potential clinical success.
The event includes a full day of workshops on August 13, followed by a two-day conference. For any further information, please contact [email protected] or download the complete guide to the event.
[ad_2]
Source link
